Skip to Content

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

In this MEDtalk, MD and Assistant Professor Paolo Strati present findings from the first-ever clinical trial testing anti-signal regulatory protein-alpha (SIRPα) antibody CC-95251 in combination with Rituximab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

Paolo Strati

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top